Dark

DYN
Dyne Therapeutics, Inc. Common Stock
stock NASDAQ

At Close

May 30, 2025 3:59:55 PM EDT

11.97USD-2.206%(-0.27)1,132,995

0.00Bid 0.00Ask 0.00Spread

Pre-market

May 30, 2025 8:09:30 AM EDT

12.24USD0.000%(0.00)739

After-hours

May 30, 2025 4:02:30 PM EDT

11.96USD-0.250%(-0.03)35,320

OverviewOptionsHistoricalExchangesShortsNews

Jan 23, 2022

12:19PM EST Pomerantz LLP is investigating claims on behalf of investors of Dyne Therapeutics, Inc. (Dyne or the Company) (NASDAQ: DYN). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. GlobeNewswire Inc

Jan 18, 2022

02:33PM EST Mid-Afternoon Market Update: Dow Dips 500 Points; NeuroMetrix Shares Spike Higher Benzinga

12:09PM EST Mid-Day Market Update: Nasdaq Tumbles 250 Points; Activision Blizzard Shares Jump Benzinga

08:19AM EST Dyne Therapeutics Announces FDA Clinical Hold On IND Application For DYNE-251 In Duchenne Muscular Dystrophy Benzinga

08:00AM EST Dyne Therapeutics Announces FDA Clinical Hold on IND Application GlobeNewswire Inc

Jan 5, 2022

07:30AM EST Dyne Therapeutics to Present at the 40th Annual J.P. Morgan GlobeNewswire Inc

Dec 2, 2021

08:30AM EST - DYNE-251, Dynes First DMD Program, is Being Developed for Patients with Mutations Amenable to Skipping Exon 51 - GlobeNewswire Inc

Nov 4, 2021

09:22AM EDT Dyne Therapeutics S-3 Shows Registration For $400M Mixed Securities Shelf Offering Benzinga

08:29AM EDT Dyne Therapeutics Q3 EPS $(0.83) Up From $(2.01) YoY Benzinga

07:30AM EDT - Robust In Vivo Data Presented at Scientific Meetings Support Advancement of Dynes Co-lead Candidates into the Clinic - GlobeNewswire Inc

Oct 13, 2021

01:38PM EDT Dyne Therapeutics Highlights Preclinical Data And Clinical Development Plans For DMD And DM1 Programs at Inaugural R&D Day Benzinga

07:45AM EDT - Investigational New Drug (IND) Submissions Anticipated for DYNE-251 in DMD During the Fourth Quarter of 2021 and for DYNE-101 in DM1 During the First Quarter of 2022 - GlobeNewswire Inc

Oct 1, 2021

10:21AM EDT Dyne Therapeutics Highlights New Preclinical Data For Duchenne Muscular Dystrophy Program Benzinga

07:32AM EDT Dyne Therapeutics Highlights Presentation Of New In Vivo Data For Duchenne Muscular Dystrophy Program During Muscle Study Group Annual Scientific Meeting Demonstrating Robust And Durable Exon Skipping And Dystrophin Expression Benzinga

07:30AM EDT - Dystrophin Restoration of 90% of Wild-Type Levels Observed in the Diaphragm and 78% in the Heart with ~80% Dystrophin-Positive Fibers After a Single Dose in mdx Mouse Model - GlobeNewswire Inc

Sep 28, 2021

07:30AM EDT - The Muscle to Move to the Clinic Event Will Highlight Preclinical Data Supporting Advancement of Dynes DM1 and DMD Programs Toward Clinical Trials and Anticipated Timelines, and Feature Leading Experts in Both Disease Areas - GlobeNewswire Inc

Sep 27, 2021

07:39AM EDT Dyne Therapeutics To Present At Chardan's Virtual 5th Annual Genetic Medicines Conference Benzinga

07:30AM EDT Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to present during Chardans Virtual 5th Annual Genetic Medicines Conference. GlobeNewswire Inc

Sep 20, 2021

07:36AM EDT Dyne Therapeutics Presents New In Vivo Data For Its Myotonic Dystrophy Type 1 Candidate Demonstrating Robust Splicing Correction During World Muscle Society 2021 Virtual Congress Benzinga

07:30AM EDT - New In Vivo Data Also Show Sustained Knockdown of Toxic Human Nuclear DMPK RNA and Foci Reduction - GlobeNewswire Inc

Aug 5, 2021

08:03AM EDT Dyne Therapeutics Q2 EPS $(0.58) Up From $(3.31) YoY Benzinga

07:30AM EDT - On Track to Submit INDs for DM1, DMD and FSHD Programs Between the Fourth Quarter of 2021 and the Fourth Quarter of 2022 - GlobeNewswire Inc

Jun 25, 2021

07:32AM EDT Dyne Therapetuics Highlights Presentation Of Preclinical Data From Facioscapulohumeral Musclar Dystrophy Program During FSHD Society Int'l. Research Congress Benzinga

07:30AM EDT - FORCE platform enables targeted muscle delivery with lead FSHD program candidate demonstrating potent suppression of DUX4 biomarkers in patient cell line - GlobeNewswire Inc

Jun 3, 2021

08:23AM EDT The Daily Biotech Pulse: Merck Completes Organon Spin-Off, Auris Repositions As RNA Therapeutic Company With Trasir Purchase, Replimune's Readout Benzinga

Jun 2, 2021

04:05PM EDT - Co-founder Romesh Subramanian, Ph.D., stepping down as chief scientific officer and will serve as an advisor after leading successful R&D and pipeline-building efforts - GlobeNewswire Inc

May 26, 2021

07:30AM EDT Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 9:00 a.m. ET. GlobeNewswire Inc

May 14, 2021

02:44PM EDT Dyne Therapeutics' Myotonic Dystrophy Gene Therapy Shows Encouraging Action In Animal Studies Benzinga

07:07AM EDT Dyne Therapeutics Highlights Presentation Of New Preclinical Data From Its Myotonic Dystrophy Type 1 Program During American Society of Gene & Cell Therapy Annual Meeting Benzinga

07:00AM EDT - Robust Reduction in DMPK RNA in Multiple Muscles at Four Weeks in Novel In Vivo Model Developed by Dyne; Additional In Vitro Data Support Advancement of Lead DM1 Candidate - GlobeNewswire Inc

May 6, 2021

08:38AM EDT Dyne Therapeutics Q1 2021 EPS $(0.50) Beats $(0.60) Est Benzinga

07:29AM EDT - On Track to Submit INDs for DM1, DMD and FSHD Programs Between the Fourth Quarter of 2021 and the Fourth Quarter of 2022 - GlobeNewswire Inc

Apr 27, 2021

04:59PM EDT New Preclinical Data from Dyne Therapeutics' Myotonic Dystrophy Type 1 Program to be Featured in Presentations During Upcoming American Society of Gene & Cell Therapy Annual Meeting Benzinga

Mar 25, 2021

07:58AM EDT The Daily Biotech Pulse: Bristol-Myers Squibb's Skin Cancer Readout, Cellect Strikes Reverse Merger Deal, Lava Therapeutics Makes Nasdaq Debut Benzinga

Mar 4, 2021

07:39AM EST Dyne Therapeutics Q4 EPS $(0.64) Up From $(2.10) YoY Benzinga

07:35AM EST - Preclinical Data Further Validate FORCE Platform; Driving Toward IND Submissions for DM1, DMD and FSHD Programs Between Q421 and Q422 - GlobeNewswire Inc

07:25AM EST Seasoned Clinical Leader Brings Deep Experience in Drug Development, Including Approval of an Oligonucleotide Therapy in Neuromuscular Disease GlobeNewswire Inc

Feb 8, 2021

07:30AM EST Dr. Dugar Brings Over 20 Years of Experience in Medical Affairs, Clinical and Commercial Development, and Real-World Evidence, Including in Rare Muscle Disease GlobeNewswire Inc

Jan 21, 2021

02:46PM EST Mid-Day Market Update: Nasdaq Rises Over 50 Points; Dyne Therapeutics Shares Plummet Benzinga

02:46PM EST Mid-Afternoon Market Update: Dow Rises 50 Points; Vinco Ventures Shares Spike Higher Benzinga

12:07PM EST Mid-Day Market Update: Nasdaq Rises Over 50 Points; Dyne Therapeutics Shares Plummet Benzinga

08:05AM EST The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping Benzinga

05:43AM EST Dyne Therapeutics Priced 6M Share Public Offering of Common Stock @$28/Share Benzinga

Jan 20, 2021

08:59PM EST Dyne Therapeutics Prices Underwritten Public Offering Of 6 Mln Shares At $28.00/shr RTTNews

08:05PM EST Dyne Therapeutics Announces Pricing of $168 Million Public Offering GlobeNewswire Inc

Jan 19, 2021

08:18AM EST Dyne Therapeutics Files For 5.5M Share Common Stock Offering Benzinga

Jan 15, 2021

07:57AM EST The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges Benzinga

Jan 14, 2021

07:57AM EST The Daily Biotech Pulse: Alexion Pauses COVID-19 Study, NantKwest Readout, Organogenesis Jumps On Guidance, Trial Updates Benzinga

Jan 13, 2021

07:25AM EST The Daily Biotech Pulse: Bausch Health Issues Positive Pre-Announcement, Acorda Streamlines Operations Benzinga

Jan 12, 2021

08:16AM EST The Daily Biotech Pulse: GSK, Vir To Start COVID-19 Antibody Study, Novartis In-Licenses BeiGene's Cancer Drug, Earnings Preannouncements Continue Benzinga

Jan 10, 2021

05:10PM EST Dyne Therapeutics Announced Myotonic Dystrophy Type 1 Program Achieved Robust RNA Knock Down of Toxic Human Nuclear DMPK in Preclinical Study Benzinga

03:00PM EST - In Vivo Model Developed by Dyne Sets New Standard for EvaluatingPharmacodynamics in DM1 - GlobeNewswire Inc

Jan 5, 2021

07:30AM EST Dyne Therapeutics to Present at 39th Annual J.P. Morgan Healthcare GlobeNewswire Inc

Dec 8, 2020

10:17AM EST Cerevance, a private drug discovery and development company focused on brain diseases, today announced the appointment of David Lubner, a senior finance executive with more than 25 years of experience in the life sciences industry, to Cerevances Board of Directors. GlobeNewswire Inc

Nov 9, 2020

07:30AM EST Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management will present at upcoming virtual investor conferences. GlobeNewswire Inc

Nov 5, 2020

07:42AM EST Dyne Therapeutics Q3 EPS $(2.01) Up From $(2.36) YoY Benzinga

07:35AM EST - Successful Financings, including $268 Million Initial Public Offering and $116 Million Series B Expected to Fund Through Proof of Concept Data in Co-lead Programs, Myotonic Dystrophy Type 1 and Duchenne Muscular Dystrophy - GlobeNewswire Inc

Oct 20, 2020

08:17AM EDT The Daily Biotech Pulse: Aptinyx Jumps On Positive Readout, Cara Executes Korsuva Licensing Deal, Cleveland BioLabs Rallies On Reverse Merger Benzinga

Oct 12, 2020

12:39PM EDT JP Morgan Initiates Coverage On Dyne Therapeutics with Overweight Rating, Announces Price Target of $27 Benzinga

09:47AM EDT Benzinga's Top Upgrades, Downgrades For October 12, 2020 Benzinga

08:11AM EDT Stifel Initiates Coverage On Dyne Therapeutics with Buy Rating, Announces Price Target of $29 Benzinga

05:25AM EDT Jefferies Initiates Coverage On Dyne Therapeutics with Buy Rating, Announces Price Target of $47 Benzinga

04:55AM EDT Piper Sandler Initiates Coverage On Dyne Therapeutics with Overweight Rating, Announces Price Target of $34 Benzinga

Oct 1, 2020

04:44PM EDT VV Manager II Discloses 6.5% Active Stake In Dyne Therapeutics Benzinga

Sep 21, 2020

04:05PM EDT Dyne Therapeutics Announces Closing of Initial Public Offering GlobeNewswire Inc

Sep 17, 2020

01:25PM EDT Dyne Therapeutics Shares Open For Trade At $22.59; IPO Priced At $19/Share Benzinga

09:45AM EDT Dyne Therapeutics Shares Expected To Open For Quote At 10:35 a.m. EDT, Expected To Open For Trade After 10:45 a.m. EDT; IPO Priced At $19/Share Benzinga

Sep 16, 2020

07:00PM EDT Dyne Therapeutics Announces Pricing of Initial Public Offering GlobeNewswire Inc

08:35AM EDT IPO Outlook For The Week: Snowflake and Amwell Lead Busy 12 IPO Lineup Benzinga